Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis

Human T cell leukaemia/lymphoma virus infection in pregnant women in the United Kingdom: population study

“…The prevalence of HIV nationally in 1998 was 0.04/1000 in eligible first time blood donations and 0.004/1000 in repeat donations 42. Although the risks of infection and disease after contaminated transfusion are less with HTLV than with HIV,43 44 screening first time donors for HTLV would not be inconsistent with the present policy of screening all donations for HIV.…”

Comparative evaluation of 14 immunoassays for detection of antibodies to the human T‐lymphotropic virus types I and II using panels of sera from Sweden and West Africa

“… ‡Based on the HTLV‐I seroprevalence rate (7/300,000) found among Swedish blood donors 1994‐95 16 . The specificity data (initial results) from testing of the Swedish panel were used for the calculations of the positive predictive values. …”

HTLV-I/II associated disease in England and Wales, 1993-7: retrospective review of serology requests

“…These data have important implications for cost efficacy studies of interventions to prevent HTLV-I transmission in Europe (for example, antenatal or blood donor screening) as until now analysts have mainly relied on Japanese data 5. Furthermore, the possibility of other HTLV-I associated conditions (uveitis, arthritis, alveolitis) seems to be rarely considered by clinicians.…”